Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2020

View Archived Issues

Antigen agnostic tolerizing therapy in MS

Small-molecule compound targets amyloid beta

FDA places IND on hold for PRAX-114 in major depressive disorder

BRKB-28 shows promising in vitro efficacy in breast and gastric cancer

Phase I data reported for Medicago's COVID-19 vaccine candidate

Preliminary phase I data for AT-301 nasal spray being developed for COVID-19

Ariagen patents AhR agonists for cancer

Janssen Pharmaceutica discloses BARK1 inhibitors

Colorado Research Partners identifies KHK inhibitors

NiKang Therapeutics synthesizes new HIF-2alpha inhibitors

New oncolytic adenoviral vectors presented by Targovax

SHR-0302 displays dose-dependent effects in rheumatoid arthritis

First-in-human data for LNA-043 as treatment of knee osteoarthritis

Rallybio begins phase I/II study of RLYB-211 for fetal and neonatal alloimmune thrombocytopenia

Phase II trial of bemarituzumab in gastric or GEJ cancer meets primary endpoints

Promising phase II data for deucravacitinib in active psoriatic arthritis

[64Cu]DOTA-UBI 29-41 for imaging of active infectious processes

First phase IIa data presented on AR-882, a potent and selective uricosuric drug

Small molecule targets same repeat expansion in distinct diseases

Corbus reports post-hoc analyses of RESOLVE-1 study of lenabasum for systemic sclerosis

Ono initiates phase III study of Foipan for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...